top of page
We develop and characterize nanobodies that present tight and specific binding and internalization into PSMA or RTK positive cells and that accumulate specifically in PSMA or RTK positive tumors. We then conjugate these nanobodies to cytotoxic drugs, and we show that the conjugate internalizes specifically into PSMA or RTK positive cells, where the drug is released and induces cytotoxic activity both in cells and in preclinical models of cancer.
Nanobodies Targeting Prostate-Specific Membrane Antigen for the Imaging and Therapy of Prostate Cancer.
Rosenfeld L, Sananes A, Zur Y, Cohen S, Dhara K, Gelkop S, Ben Zeev E, Shahar A, Lobel L, Akabayov B, Arbely E, Papo N. J Med Chem. 2020.
bottom of page